Quince Therapeutics (QNCX) Capital Expenditures (2018 - 2025)
Quince Therapeutics (QNCX) posted Capital Expenditures of $4000.0 for Q4 2025, down 94.59% on a QoQ basis from $74000.0 in Q3 2025, and down 96.99% year-over-year from $133000.0 in Q4 2024.
Powered by 
Analysis
Quince Therapeutics (QNCX) Capital Expenditures (2018 - 2025) Analysis & Trends
Quince Therapeutics has reported Capital Expenditures for 8 years, with the latest figure at $4000.0 in Q4 2025.
- On a quarterly basis, Capital Expenditures fell 96.99% year-over-year to $4000.0 in Q4 2025; TTM through Jun 2026 was $78000.0, a 82.78% decrease from a year earlier, with the FY2025 full-year figure at $352000.0, up 36.96% from the prior year.
- Capital Expenditures was $4000.0 for Q4 2025 at Quince Therapeutics, down from $74000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $148000.0 in Q1 2025, with the low at $4000.0 in Q4 2025.
- Average Capital Expenditures over 5 years is $67625.0, with a median of $48000.0 recorded in 2022.
- The sharpest annual moves came in 2023 and 2025: Capital Expenditures surged 2620.0% in 2023, then sank 96.99% in 2025.
- Over 5 years, Capital Expenditures stood at $44000.0 in 2021, then surged by 77.27% to $78000.0 in 2022, then tumbled by 69.23% to $24000.0 in 2023, then surged by 454.17% to $133000.0 in 2024, then tumbled by 96.99% to $4000.0 in 2025.
- The last three Capital Expenditures figures came in at $4000.0 (Q4 2025), $74000.0 (Q3 2025), and $126000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 513.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 140.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 112.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 240.20 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 37.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 40.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -1.87 Mn |
| 10 | Quince Therapeutics | 175.52 Mn | 175.52 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 4,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Jun 30, 2025 | 126,000.00 |
| Mar 31, 2025 | 148,000.00 |
| Dec 31, 2024 | 133,000.00 |
| Sep 30, 2024 | 46,000.00 |
| Jun 30, 2024 | 39,000.00 |
| Mar 31, 2024 | 39,000.00 |
| Dec 31, 2023 | 24,000.00 |
| Mar 31, 2023 | 136,000.00 |
| Dec 31, 2022 | 78,000.00 |
| Sep 30, 2022 | 50,000.00 |
| Mar 31, 2022 | 5,000.00 |
| Dec 31, 2021 | 44,000.00 |
| Jun 30, 2021 | 99,000.00 |
| Mar 31, 2021 | 37,000.00 |
| Dec 31, 2020 | -220,000.00 |
| Sep 30, 2020 | 20,000.00 |
| Jun 30, 2020 | 17,000.00 |
| Mar 31, 2020 | 5,000.00 |